- Vienna '18
- Athens 2019
- ESCRS Player
- On Demand
- ESCRS iLearn
- ESCRS YO's
First Author: O.Richoz SWITZERLAND
Co Author(s): F. Hafezi
Back to previous
In addition to arresting keratoconus, CXL shows promising results for the treatment of corneal infections, one of the leading causes of global blindness. Currently, only corneal specialists perform CXL within the contraints of a sterile operating room. The new device will allow the comprehensive ophthalmologist in remote areas to perform CXL at the slit lamp in an efficient and low-cost manner.
Dept. of Ophthalmology, Geneva University Hospitals, Geneva, Switzerland
The new device is custom-fit for any standard slit lamp and utilizes a patented safety mechanism that analyzes riboflavin fluorescence. Since the UV-A fluence is constant, the fluorescence intensity depends only on the riboflavin concentration. If the concentration is too low, the device will not allow irradiation.
Using optimized treatment parameters, we were able to reduce methicillin-resistant Staphylococcus aureus strains by 2 log units (99.9%) after an irradiation time of 120 seconds.
Additional clinical research data on the use of CXL in corneal infections is forthcoming. The University of Geneva have several pending patents on the CXL corneal treatment apparatus.
... has significant investment interest in a company producing, developing or supplying product or procedure presented